First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
NIH study sIntranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
Precipio launched COVID-19 antibody testing at point-of-care
On Jan. 28, 2021, Precipio announced that following receipt of an Emergency Use Authorization from the U.S. Food…
Lilly, Vir Biotechnology and GSK announced first patient dosed in expanded BLAZE-4 trial for COVID-19
On Jan. 27, 2021, Eli Lilly, Vir Biotechnology and GlaxoSmithKline announced a collaboration to evaluate a combination of…
Nirmidas Biotech received FDA Emergency Use Authorization for its COVID-19 rapid antibody fingerstick test
On Jan. 25, 2021, Nirmidas Biotech announced its second FDA Emergency Use Authorization (EUA) for their COVID-19 rapid…
OHSU study revealed SARS-CoV-2 reacted to antibodies of virus from 2003 SARS outbreak
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
Just – Evotec Biologics expanded contract with Department of Defense for manufacturing of monoclonal antibodies
On Jan. 25, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
TGen-NAU study results showed COVID-19 virus triggers antibodies from previous coronavirus infections
On Jan. 19, 2021, the Northern Arizona University and TGen, an affiliate of City of Hope, announced results…
AXIM released manuscript describing rapid point-of-care test that measures COVID-19 neutralizing antibodies
On Jan. 11, 2021, AXIM Biotechnologies announced that it had released a preprint of its manuscript describing the…
In vitro study showed Pfizer-BioNTech COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 with mutation
On Jan. 8, 2021, Pfizer and BioNTech announced results from an in vitro study conducted by Pfizer and…
Large clinical trial tested combination monoclonal antibody therapy for mild/moderate COVID-19
On Jan. 5, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announed that a phase 2/3…
Novavax initiated PREVENT-19 pivotal phase 3 efficacy trial of COVID-19 vaccine in the US and Mexico
On Dec. 28, 2020, Novavax announced initiation of PREVENT-19, its pivotal Phase 3 study in the U.S. and…
NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…
OraSure updated Its Emergency Use Authorization application for lab-based oral SARS-CoV-2 antibody test
On Dec. 21, 2020, OraSure Technologies disclosed that the FDA had requested additional information as part of its…
Investigational COVID-19 therapeutics evaluated in large clinical trials
On Dec. 17, 2020, NIAID announced that two randomized, controlled Phase 3 clinical trials had begun evaluating investigational…
ACON Laboratories received Emergency Use Authorization for its SARS-COV-2 IgG/IgM rapid test
On Dec. 17, 2020, ACON Laboratories announced that its SARS-COV-2 IgG/IgM Rapid Test has been authorized for emergency…
RedHill’s phase 2/3 COVID-19 candidate opaganib reduced ARDS-related blood clotting in preclinical model
On Dec. 15, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
Abbott received CE Mark for its COVID-19 IgG quantitative antibody blood test
On Dec. 15, 2020, Abbott announced it received had CE Mark for its new quantitative SARS-CoV-2 IgG (Immunoglobulin…
AXIM Biotechnologies completed successful Covid-19 live virus test and filed amended EUA
On Dec. 15, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
Antibody study suggested COVID-19 infections underestimated
On Dec. 14, 2020, a months long study to determine the number of Houstonians carrying COVID-19 antibodies revealed…
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 10, 2020, Roche announced a partnership with Moderna to utilise the Elecsysï¾® Anti-SARS-CoV-2 S antibody test…
ImmunityBioï¾’s hAd5 T-Cell COVID-19 vaccine candidate showed complete protection of airways
On Dec. 10, 2020, ImmunityBio announced its COVID-19 vaccine candidate protected nasal and lung airways of non-human primates…
Roche partnered with Moderna to include SARS-CoV-2 antibody test in ongoing COVID-19 vaccine trials
On Dec. 9, 2020, Roche announced a partnership with Moderna to utilise the Elecsysï¾® Anti-SARS-CoV-2 S antibody test…
Mount Sinai researchers advanced universal influenza virus vaccine
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
Moderna updated on clinical development and production of Its COVID-19 vaccine candidate
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
AXIM Biotechnologies filed patent for virus binding recombinant protein for SARS-CoV-2 and began manufacturing
On Dec. 3, 2020, AXIM Biotechnologies announced the development and patent filing for an enzyme-linked immunosorbent assay (ELISA)-based…
Roche received FDA Emergency Use Authorization for new test to measure level of SARS-CoV-2 antibodies
On Dec. 2, 2020, Roche announced that its Elecsysï¾® Anti-SARS-CoV-2 S antibody test had received Emergency Use Authorization…
City of Hope coronavirus vaccine produced strong immunity in preclinical research
On Nov. 30, 2020, the City of Hope reported that its investigational vaccine produced strong protective immunity against…
Less than 10% of people in the U.S. had detectable SARS-CoV-2 antibodies as of September 2020
On Nov. 24, 2020, JAMA reported that fewer than 10% of people in tye U.S. as of September…
XBiotech data showed effective anti-virus activity for antibodies in candidate influenza-COVID-19 therapeutic
On Nov. 19, 2020, XBiotech announced data for its breakthrough candidate therapy for treating infections of influenza and…